Label Image (Lbl500905038)
Pregabalin Capsule
Product Images NDC 50090-5038
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 50090-5038). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Pregabalin Fig01)
Figure 2 (Pregabalin Fig02)
This is a table that shows the percentage improvement in pain from baseline after taking Pregabalin 160 mg for three days. The table includes numbers 100, 2, 10, and several other numbers in the columns. The meaning of these numbers is not clear. The text also includes a mention of the Facebook website, but it is not related to the table.*
Figure 3 (Pregabalin Fig03)
Figure 4 (Pregabalin Fig04)
Figure 5 (Pregabalin Fig05)
This appears to be a table or chart displaying dosages of two medications (Fregabalin and Pregataiin) as well as a placebo, with a corresponding chart showing the percentage of patients who improved while taking each medication. The chart also displays percentage improvement in pain from a baseline. However, as the text is not entirely readable and some information is missing or incomplete, a full understanding of the table's contents cannot be accurately determined.*
Figure 6 (Pregabalin Fig06)
This appears to be a table showing the results of different studies and dosages, with placebo and different medication strengths. There is mention of statistical significance. The text is readable but needs formatting to be more clear.*
Figure 7 (Pregabalin Fig07)
Figure 9 (Pregabalin Fig08)
This text provides a graph showing the percentage improvement in pain from baseline for patients who received either a daily dose of 300mg or 450mg of Pregabalin compared to a placebo. The percentages range from 0-100 with the highest improvement seen in the group receiving 450mg of Pregabalin. There is no additional information provided.*
Figure 10 (Pregabalin Fig09)
This appears to be a chart displaying the estimated percentage of subjects without LTR (possibly referring to a medical condition or treatment) over a period of 120 days. The percentages range from 0% to 100%, with markers for different intervals marked along the x-axis. There are two sets of data represented by different markers, one labeled "Progabain" and the other "Placebo".*
Figure 11 (Pregabalin Fig10)
Figure 12 (Pregabalin Fig11)
This is a chart showing the percentage of subjects who showed improvement in a study conducted over 16 weeks with Pregabalin and Placebo. The Y-axis shows the percentage ranging from 0% to 100%. The X-axis indicates the range of improvement percentage from baseline to week 16. There are numerical values ranging from 210 to 280.*
Cockcroft And Gault Equation (Pregabalin Formula)
This text appears to be a formula for calculating the creatinine clearance, a measure of kidney function. It involves multiplying the result of subtracting the age of the patient in years from 140, by their weight in kilograms, and then multiplying that result by 0.85 if the patient is female. The final step is to multiply the result by the serum creatinine level in milligrams per deciliter, and then divide that by 72.*
Chemical Structure (Pregabalin Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
